Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. Among authors: mouret reynier ma. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
Measurement of residual disease after neoadjuvant chemotherapy.
Abrial C, Thivat E, Tacca O, Durando X, Mouret-Reynier MA, Gimbergues P, Penault-Llorca F, Chollet P. Abrial C, et al. Among authors: mouret reynier ma. J Clin Oncol. 2008 Jun 20;26(18):3094; author reply 3095. doi: 10.1200/JCO.2008.16.7817. J Clin Oncol. 2008. PMID: 18565900 No abstract available.
Long-term significance (15 years) of pathological complete response after dose-dense neoadjuvant chemotherapy in breast cancer.
Wang-Lopez Q, Abrial C, Planchat E, Mouret-Reynier MA, Cure H, Gimbergues P, Dubray-Longeras P, Gadea E, Kwiatkowski F, Penault-Llorca F, Chollet P, Durando X. Wang-Lopez Q, et al. Among authors: mouret reynier ma. Breast J. 2013 Jul-Aug;19(4):448-50. doi: 10.1111/tbj.12131. Epub 2013 Jun 11. Breast J. 2013. PMID: 23750595 No abstract available.
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P. Abrial SC, et al. Among authors: mouret reynier ma. Breast Cancer Res Treat. 2005 Dec;94(3):255-63. doi: 10.1007/s10549-005-9008-8. Breast Cancer Res Treat. 2005. PMID: 16267618
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.
Gay-Bellile M, Véronèse L, Combes P, Eymard-Pierre E, Kwiatkowski F, Dauplat MM, Cayre A, Privat M, Abrial C, Bignon YJ, Mouret-Reynier MA, Vago P, Penault-Llorca F, Tchirkov A. Gay-Bellile M, et al. Among authors: mouret reynier ma. Oncotarget. 2017 Aug 24;8(44):77540-77551. doi: 10.18632/oncotarget.20560. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100407 Free PMC article.
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. du Bois A, et al. Among authors: mouret reynier ma. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15. J Clin Oncol. 2014. PMID: 25225436 Clinical Trial.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A. Jacot W, et al. Among authors: mouret reynier ma. Int J Cancer. 2019 Dec 15;145(12):3359-3369. doi: 10.1002/ijc.32402. Epub 2019 Jun 20. Int J Cancer. 2019. PMID: 31087564 Free article.
[HIPEC in ovarian cancer: What should we expect?].
Picard L, Bourgin C, Penault-Llorca F, Beguinot M, Cornou C, Le Bouedec G, Mouret-Reynier MA, Selle F, Pomel C. Picard L, et al. Among authors: mouret reynier ma. Bull Cancer. 2019 Nov;106(11):1023-1028. doi: 10.1016/j.bulcan.2019.04.003. Epub 2019 May 22. Bull Cancer. 2019. PMID: 31126679 Review. French.
147 results